ribosomal protein S4X pseudogene 11Genealiases: RPS4P11 · RPS4X_2_1029
Q-omics provides the consensus-scored RPS4XP11 profile across patient tissues and cancer cell-line models. RPS4XP11 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RPS4XP11 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RPS4XP11 RNA expression shows 11,466 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, KIRC, and TGCT as cancer lineages where RPS4XP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS4XP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS4XP11 survival associations across molecular data types. RPS4XP11 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS4XP11 RNA expression–survival associations across cancer types. High RPS4XP11 expression shows unfavorable associations in LUAD, KIRP and SARC, but favorable associations in CESC, LUSC and BLCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RPS4XP11 RNA expression.
This table summarizes RPS4XP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS4XP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS4XP11 shows lower tumor expression in UCEC and higher tumor expression in KIRC, THCA, COAD, LUAD and CHOL. The KIRC box plot shows higher RPS4XP11 RNA expression in tumor versus normal tissue (log2 FC = +0.251, t-test p < 0.001).
This table shows molecular features associated with RPS4XP11 in patient tissues and cancer cell lines. In patient samples, RPS4XP11 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
